Compare PCT & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PCT | SLBT |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Environmental Services | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 846.7M |
| IPO Year | 2020 | 2025 |
| Metric | PCT | SLBT |
|---|---|---|
| Price | $3.60 | $1.51 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.60 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 84.0K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,355,000.00 | N/A |
| Revenue This Year | $269.48 | N/A |
| Revenue Next Year | $262.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.60 | $1.42 |
| 52 Week High | $15.49 | $6.25 |
| Indicator | PCT | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 21.67 | 33.29 |
| Support Level | N/A | $1.42 |
| Resistance Level | $6.23 | $1.98 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 0.75 | 17.82 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.